Industry & Policy News

[Mainz Biomed] Mainz Biomed announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz, the development bank of the German federal state of Rheinland-Pfalz.

[PanTher Therapeutics (BioSpace)] PanTher Therapeutics announced that the first patient has been treated with PTM-101 in a Phase Ib clinical trial in PDAC. PTM-101 is the most advanced product candidate within PanTher’s portfolio of innovative formulations for continuous, high-dose, localized drug administration directly to the site of the tumor.

[Nature] Supercharged ‘natural killer’ cells could become a potent way to reset a disordered immune system — and thus quench some autoimmune disorders.

[HeartBeat.bio (Biotech Newswire)] HeartBeat.bio AG and biotx.ai GmbH announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal mapping of the genome for target discovery with HeartBeat.bio’s human-based Cardioid Drug Discovery Platform to drive innovation in heart failure drug development.

[Iridex Corporation (BioSpace)] Iridex Corporation announced that the first patient has been enrolled in the investigator-led DAME Trial to evaluate the clinical efficacy, safety, cost-effectiveness, and patient acceptability of adding subthreshold MicroPulse treatments to anti-vascular endothelial growth factor therapy in patients presenting with severe diabetic macular edema.

[CytoDyn, Inc.] CytoDyn, Inc. announced that the first patient has been dosed in the Company’s clinical trial evaluating the efficacy of leronlimab in patients with relapsed/refractory microsatellite stable colorectal cancer.